ARS Pharma names President Donn Casale CEO, replacing co-founder Richard Lowenthal

ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc.

SPRY

0.00
  • ARS Pharmaceuticals named President Donn Casale as CEO and director, effective July 7, 2026.
  • Co-founder Richard Lowenthal exited as an employee and officer, effective July 6, 2026.
  • Casale previously served as Dynavax chief commercial officer, scaling HEPLISAV-B to over $300 million annualized revenue and over 50% U.S. share.
  • He also held leadership roles at Depomed, earlier spent 14 years at Merck across sales, marketing, corporate strategy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ARS Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607071630PRIMZONEFULLFEED9758506) on July 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.